Natalizumab and the role of α₄-integrin antagonism in the treatment of multiple sclerosis

By O’Connor Paul  

Expert Opinion on Biological Therapy, Vol. 7, Iss. 1, 2007-01 ,pp. : 123-136

Informa Healthcare

Access to resources Recommend Favorite

Interleukin 18 gene polymorphism is a risk factor for multiple sclerosis

By Karakas Celik Sevim   Öz Zehra   Dursun Ahmet   Unal Aysun   Emre Ufuk   Cicek Salih   Keni Fatih  

Molecular Biology Reports, Vol. 41, Iss. 3, 2014-03 ,pp. : 1653-1658

Springer Publishing Company

Access to resources Recommend Favorite

Tovaxin for multiple sclerosis

By Rivera Victor M  

Expert Opinion on Biological Therapy, Vol. 11, Iss. 7, 2011-07 ,pp. : 961-967

Informa Healthcare

Access to resources Recommend Favorite

Alemtuzumab and multiple sclerosis: therapeutic application

By Alireza Minagar   J Steven Alexander   Mohammad Ali Sahraian   Robert Zivadinov  

Expert Opinion on Biological Therapy, Vol. 10, Iss. 3, 2010-03 ,pp. : 421-429

Informa Healthcare

Access to resources Recommend Favorite

Current evaluation of alemtuzumab in multiple sclerosis

By Coyle Patricia Katherine  

Expert Opinion on Biological Therapy, Vol. 14, Iss. 1, 2014-01 ,pp. : 127-135

Informa Healthcare

Access to resources Recommend Favorite